Your browser is no longer supported. Please, upgrade your browser.
ORPH [NASD]
Orphazyme A/S
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand34.95M Perf Week-2.55%
Market Cap160.08M Forward P/E- EPS next Y-2.79 Insider Trans- Shs Float28.14M Perf Month-36.48%
Income- PEG- EPS next Q-0.70 Inst Own0.83% Short Float1.83% Perf Quarter-49.11%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.04 Perf Half Y-61.87%
Book/sh- P/B- EPS next Y16.50% ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range4.60 - 77.77 Perf YTD-57.32%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-94.11% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low-0.43% ATR0.51
Employees141 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)40.13 Volatility4.85% 8.79%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.08 Prev Close4.75
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume11.88M Price4.58
Recom4.00 SMA20-17.71% SMA50-33.41% SMA200-52.53% Volume911,370 Change-3.58%
Jun-21-21Downgrade Guggenheim Buy → Sell
Mar-30-21Downgrade BofA Securities Neutral → Underperform $13 → $5
Oct-26-20Initiated Guggenheim Buy $27
Oct-26-20Initiated BofA Securities Buy $13
Aug-03-21 04:04PM  
11:20AM  
10:00AM  
Aug-02-21 10:35PM  
Jul-30-21 07:40PM  
02:52PM  
Jul-29-21 12:30PM  
Jul-28-21 09:37PM  
08:33PM  
04:00PM  
11:00AM  
Jul-27-21 11:35AM  
11:00AM  
09:58AM  
08:00AM  
Jul-26-21 02:12PM  
01:00PM  
09:59AM  
Jul-25-21 11:20AM  
Jul-23-21 09:27PM  
10:15AM  
10:00AM  
Jul-22-21 12:30PM  
11:30AM  
10:14AM  
Jul-21-21 09:30PM  
08:00PM  
02:54PM  
02:00PM  
11:00AM  
10:13AM  
Jul-20-21 03:00PM  
02:04PM  
01:00PM  
10:12AM  
Jul-19-21 06:01PM  
03:15PM  
11:00AM  
09:00AM  
12:40AM  
Jul-18-21 09:15AM  
Jul-17-21 11:22AM  
10:18AM  
08:00AM  
Jul-16-21 04:00PM  
02:06PM  
12:30PM  
11:58AM  
11:00AM  
10:40AM  
Jul-15-21 06:41PM  
05:00PM  
03:00PM  
01:40PM  
11:00AM  
10:04AM  
10:00AM  
09:42AM  
09:00AM  
Jul-14-21 09:00PM  
02:54PM  
12:55PM  
12:55PM  
11:00AM  
09:37AM  
09:01AM  
01:30AM  
Jul-13-21 07:21PM  
04:07PM  
01:51PM  
10:00AM  
09:22AM  
Jul-12-21 10:00PM  
04:11PM  
11:45AM  
11:35AM  
12:30AM  
Jul-09-21 10:03PM  
Jun-28-21 02:00AM  
12:00AM  
Jun-24-21 07:31AM  
Jun-23-21 04:22PM  
05:43AM  
Jun-21-21 12:39PM  
Jun-19-21 06:53AM  
Jun-18-21 04:11PM  
12:37PM  
06:53AM  
06:49AM  
06:17AM  
05:07AM  
01:56AM  
01:12AM  
01:00AM  
Jun-16-21 04:06PM  
Jun-15-21 12:46PM  
11:05AM  
Jun-11-21 10:12AM  
09:36AM  
09:17AM  
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.